medmix AG () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

IVF HARTMANN Holding AG

Straumann Holding AG

Medacta Group SA

COMET Holding AG

SKAN Group AG

Coltene Holding AG

Medartis Holding AG

Alcon AG

medmix AG

Metall Zug AG

Why is medmix AG ?

Weak Long Term Fundamental Strength with a -16.54% CAGR growth in Operating Profits over the last 5 years

Low ability to service debt as the company has a high Debt to EBITDA ratio of 1.93 times
The company has been able to generate a Return on Equity (avg) of 3.30% signifying low profitability per unit of shareholders funds

Flat results in Jun 25

CASH AND EQV(HY) Lowest at CHF 108.4 MM
DEBT-EQUITY RATIO (HY) Highest at 50.02 %
NET SALES(Q) Lowest at CHF 225.4 MM

With ROE of -0.22%, it has a Very Expensive valuation with a 0.90 Price to Book Value

Over the past year, while the stock has generated a return of -4.40%, its profits have fallen by -150.8%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -4.40% returns in the last 1 year, the stock has also underperformed Switzerland SMI in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is medmix AG for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

medmix AG

-100.0%

1.03

40.85%

Switzerland SMI

7.38%

0.46

15.70%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.15%

EBIT Growth (5y)

-16.54%

EBIT to Interest (avg)

4.02

Debt to EBITDA (avg)

1.93

Net Debt to Equity (avg)

0.35

Sales to Capital Employed (avg)

0.62

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.01%

ROCE (avg)

5.43%

ROE (avg)

3.30%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.90

EV to EBIT

25.04

EV to EBITDA

7.11

EV to Capital Employed

0.92

EV to Sales

1.13

PEG Ratio

Dividend Yield

ROCE (Latest)

3.69%

ROE (Latest)

-0.22%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

NET PROFIT(HY)

Higher at CHF 4.28 MM

INTEREST COVERAGE RATIO(Q)

Highest at 906.38

RAW MATERIAL COST(Y)

Fallen by -11.08% (YoY

OPERATING PROFIT(Q)

Highest at CHF 42.6 MM

OPERATING PROFIT MARGIN(Q)

Highest at 18.9 %

-5What is not working for the Company

CASH AND EQV(HY)

Lowest at CHF 108.4 MM

DEBT-EQUITY RATIO (HY)

Highest at 50.02 %

NET SALES(Q)

Lowest at CHF 225.4 MM

PRE-TAX PROFIT(Q)

Fallen at -54.17%

NET PROFIT(Q)

Fallen at -55.95%

Here's what is working for medmix AG

Interest Coverage Ratio

Highest at 906.38

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Profit

Highest at CHF 42.6 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CHF MM)

Operating Profit Margin

Highest at 18.9 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Raw Material Cost

Fallen by -11.08% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for medmix AG

Net Sales

Lowest at CHF 225.4 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CHF MM)

Pre-Tax Profit

Fallen at -54.17%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CHF MM)

Net Profit

Fallen at -55.95%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CHF MM)

Cash and Eqv

Lowest at CHF 108.4 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 50.02 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio